

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care - Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- The Mark Foundation names 2026 Emerging Leader Award recipients
- A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers











